Qualigen Therapeutics (NASDAQ:QLGN) Shares Down 0.8% – Should You Sell?

Qualigen Therapeutics, Inc. (NASDAQ:QLGN)’s share price dropped 0.8% during trading on Wednesday . The company traded as low as $1.22 and last traded at $1.28. Approximately 94,203 shares traded hands during mid-day trading, a decline of 94% from the average daily volume of 1,521,488 shares. The stock had previously closed at $1.29.

Qualigen Therapeutics Trading Down 0.8%

The firm has a market cap of $2.15 million, a price-to-earnings ratio of -0.17 and a beta of 0.24. The firm has a 50-day moving average of $1.34 and a two-hundred day moving average of $1.82.

Qualigen Therapeutics Company Profile

Qualigen Therapeutics, Inc (NASDAQ: QLGN) is a life sciences company headquartered in Westminster, Colorado, that combines immunodiagnostic reagents with novel immuno-oncology therapies. Operating through two primary business units—Qualigen Diagnostic Solutions and Qualigen BioTherapeutics—the company seeks to leverage its expertise in antibody engineering and assay development to address both clinical laboratory needs and unmet medical needs in oncology.

Through its Qualigen Diagnostic Solutions division, the company designs, manufactures and distributes immunoassay reagents, kits and related consumables for use in clinical and research laboratories.